회원가입 | 연락처 | 사이트맵 | English

      회사소개 | 리포트 | 커스텀 리서치 | 고객지원


로그인

카테고리

유/무선통신

전기/전자

디지털기기/미디어/방송

Information Technology

에너지

생명공학

화학/신소재

자동차

환경

일반소비재

마케팅/광고

금융

건설

교통/운송

소비자조사

방위/항공/우주

식음료

중공업

교육

기계

무역

스포츠/레저

해운/조선

패션

정부/정책

공예/귀금속

컴퍼니 프로파일

기타산업

 
현재위치 : HOME > 리포트 > 생명공학 > 제약
Investigation Report on China Recombinant Factor Ⅷ Market, 2010-2019
발행사 China Research and Intelligence

발행일 2015-06
분량 30 pages
서비스형태 Report
판매가격

인쇄하기

Description

Hemophilia is a hereditary bleeding disorder caused by a lack of clotting factor Ⅷ or Ⅸ, though not rare, which affects mostly males. Hemophilia A (clotting factor Ⅷ deficiency) is the most common form of the disorder. The number of the cases of hemophilia is about over 0.4 million around the world while that in China is about 0.06-0.1 million, among which 80% lack clotting factor Ⅷ while over half are in severe conditions.
Injecting clotting factor might be the only effective way to treat hemophilia. Recombinant factor Ⅷ (Kogenate Bayer) made by Bayer was approved by FDA and EMEA in 2000 to be used in many countries. In developed countries, the drugs for the prevention and treatment of hemophilia have a huge market. Apart from Bayer Schering, Baxter and Wyeth also make recombinant factor Ⅷ too.
After entering China, recombinant factor Ⅷ develops fast with annual sales value rising from less than CNY 6 million in 2009 to CNY 93.78 million in 2014 and CAGR reaching up to 76.8% during 2009-2014. Currently, recombinant factor Ⅷ in the Chinese market are all imported drugs. They mainly come from the following three companies: Baxter Bioscience Manufacturing (SW), Wyeth Farma S.A. (SP) and Bayer (the US), among which Bayer (the US) has the largest market share of 57.40% by sales value in 2014.
As hemophiliacs’ ability to pay for medical treatment keeps increasing due to economic development, the market size of recombinant factor Ⅷ in China is expected to keep expanding.

Readers can get at least the following information from this report:

-sales status of recombinant factor Ⅷ in China
-price of recombinant factor Ⅷ in Chinese market
-major manufacturers of recombinant factor Ⅷ in Chinese market
-share of dosage forms of recombinant factor Ⅷ in China
-market outlook of recombinant factor Ⅷ in China

The author suggests the following groups of people purchase this report:

-manufacturers of blood products
-investors/ research institutions interested in China blood products market
-any interest in the Chinese medicine market, please contact CRI for customized survey service


회사소개 | 개인정보보호정책 | 이용약관 | 배송/결제안내 | 이용안내

서울시 강남구 논현동 210-1 삼원빌딩 | 회사명 : (주)엘앤에치
대표전화 : 02-554-0001 / 팩스 : 02-3444-5501 / 이메일 : sales@landh.co.kr
Copyright ⓒ 2008 LNH, Inc. All rights reserved.